Regentis Biomaterials Ltd（RGNT）の株式分析

$1.180

+0.010 (+0.85%)終値時点

Loading chart…

高値: 1.220
始値: 1.172
出来高加重平均価格: 1.19
出来高: 23.20K
時価総額: —
安値: 1.160
売買代金: 27.53K
EV/EBITDA（TTM）: 0.00

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

www.regentis.co.il

AI分析 of Regentis Biomaterials Ltd (RGNT)

売り

Regentis Biomaterials Ltd is not a good buy right now due to its extremely low RSI of 26.439, indicating oversold conditions, and a staggering year-to-date decline of 82.49%.

バリュエーション指標

Regentis Biomaterials Ltd（RGNT）の現在の予想PERは0.00で、5年平均は0.00です。

予想PER

大幅な割安

5年平均 P/E

0.00

現在のP/E

0.00

割高

0.00

割安

0.00

予想EV/EBITDA

大幅な割安

5年平均 EV/EBITDA

0.00

現在のEV/EBITDA

0.00

割高

0.00

割安

0.00

予想PSR

大幅な割安

5年平均 P/S

0.00

現在のP/S

0.00

割高

0.00

割安

0.00

イベントタイムライン

2026-10-12 (ET)